FDA accepts sBLA for ULTOMIRIS® (ravulizumab-cwvz) for treatment of aHUS
Alexion announced the FDA has accepted for priority review the company’s sBLA for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for treatment of people with atypical hemolytic uremic syndrome in order to inhibit complement-mediated TMA. June 20, 2019